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FerroportinVenesection has been proposed as a treatment for hepatic iron overload in a number of chronic liver
disorders that are not primarily linked to mutations in iron metabolism genes. Our aim was to analyse the
impact of venesection on iron mobilisation in a mouse model of secondary iron overload. C57Bl/6 mice were
given oral iron supplementation with or without phlebotomy between day 0 (D0) and D22, and the results
were compared to controls without iron overload. We studied serum and tissue iron parameters, mRNA
levels of hepcidin1, ferroportin, and transferrin receptor 1, and protein levels of ferroportin in the liver and
spleen. On D0, animals with iron overload displayed elevations in iron parameters and hepatic hepcidin1
mRNA. By D22, in the absence of phlebotomies, splenic iron had increased, but transferrin saturation had
decreased. This was associated with high hepatic hepcidin1 mRNA, suggesting that iron bioavailability
decreased due to splenic iron sequestration through ferroportin protein downregulation. After 22 days with
phlebotomy treatments, control mice displayed splenic iron mobilisation that compensated for the iron lost
due to phlebotomy. In contrast, phlebotomy treatments in mice with iron overload caused anaemia due to
inadequate iron mobilisation. In conclusion, our model of secondary iron overload led to decreased plasma
iron associated with an increase in hepcidin expression and subsequent restriction of iron export from the
spleen. Our data support the importance of managing hepcidin levels before starting venesection therapy in
patients with secondary iron overload that are eligible for phlebotomy.D22, Day 0 and Day 22 of
idin; HFE, Haemochromatosis
C, Splenic Iron Content; TFR2,
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Iron is essential for life [1,2]. A balance exists between iron use,
absorption, storage, and recycling to fulﬁl the metabolic demand for
iron and maintain physiological concentrations in the plasma
compartment and in the different organs.
Hepcidin (produced from the Hamp1 gene) is a key regulator of
iron metabolism [3], and it is synthesised primarily by the liver [4].
Secreted in the plasma, hepcidin acts as a negative regulator of the
membrane protein ferroportin (Fpn; produced from the Slc40a1
gene). Ferroportin is a membrane iron exporter expressed onmacrophages and enterocytes. Plasma iron bioavailability is highly
dependent on iron recycling by macrophages and digestive iron
absorption by enterocytes; therefore, ferroportin plays a major role in
iron bioavailability [5–7]. An interaction between hepcidin and
ferroportin leads to internalisation and degradation of the ferroportin
protein [8]. Excessive hepcidin production has been associated with
reductions in iron release from macrophages and intestinal epithelial
cells [9]. Conversely, a reduction of hepcidin expression favours iron
release and plasma availability [10]. Within the plasma compartment,
iron is bound to transferrin, which permits iron delivery to cells
through the transferrin receptor 1 (produced from the TfRc gene) [11].
An imbalance in ironmetabolism leads to abnormal clinical situations,
like anaemia [12] or iron overload [13].
Most genetic conditions associated with an iron overload result
from mutations in iron metabolism genes (HFE, HJV, HAMP, and TFR2)
that are responsible for defects in hepcidin production or activity.
These defects lead to polyvisceral iron deposition, particularly in the
liver [14–17]. Other genetic disorders associated with iron overload
include mutations of the ferroportin gene, SLC40A1. Mutations in
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lead to an iron overload phenotype similar to that observed with
hepcidin deﬁciency. Conversely, mutations that inhibit ferroportin
protein expression on the cell membrane may lead to a predomi-
nantly macrophage-mediated iron sequestration and thus, decreased
plasma iron bioavailability [18].
Secondary ironoverload involving the livermayalsooccur outside the
context of haematological diseases [19], in some chronic liver diseases,
including viral hepatitis [20] and dysmetabolic hepatosiderosis [21].
Usually, when hepatic iron overload is diagnosed in the absence of
anaemia, venesection therapy is undertaken. For example, in genetic
haemochromatosis, repeated blood withdrawals induce the mobilisa-
tion of iron from storage compartments; this limits iron toxicity and
prevents complications associated with iron overload, particularly in
the liver [22]. In cases of ferroportin mutations that result in a
deﬁciency of ferroportin at the cell membrane, venesections are
sometimes poorly tolerated and may exacerbate anaemia despite the
presence of excessive iron stores [23].
Venesections are also frequently proposed as a treatment for
limiting hepatic iron excess and its deleterious consequences in the
chronic liver diseases mentioned above [24,25]. In these cases of
secondary iron overload, the tolerance and efﬁcacy of venesection
have not been fully explored. Moreover, we lack knowledge of the
mechanisms and kinetics of iron sequestration and mobilisation. A
better understanding of the mechanisms implicated in iron release
from the liver would enable improvements in therapeutic strategies
for hepatic iron mobilisation in cases of iron overload.
Therefore, our aims were to analyse the following in a mouse
model of secondary iron overload: i) the impact of venesection on
serum iron parameters and iron stores and ii) the kinetics of iron
mobilisation, with special emphasis on the expression of genes
involved in the control of iron metabolism.2. Materials and methods
2.1. Animals
Eight week old male C57Bl/6 mice were obtained from Janvier
(St Genest, France). They were maintained under standard conditions
of temperature, atmosphere, and light, and experimental procedures
were performed in agreement with French laws and regulations. All
mice had free access to tap water and food.Fig. 1. Flow chart of the experimental design. After 28 days of an iron-rich (3% iron) or norma
Then, for each group, 12 mice were subjected to a series of three phlebotomies (b) and 12 m
and condition (†).Micewere divided into twogroups (n=30mice each) thatwere fed,
ad libitum, either an iron-rich or normal RM3 (E) diet (SDS, France) for
4 weeks (Fig. 1). The iron-rich diet was supplemented, as previously
described [4,26].with 3% (3 g iron/100 gRM3 [E]) carbonyl iron (Sigma,
France). Sixmice of each groupwere then sacriﬁced (D0). Thereafter, all
micewere switched to a normal diet until day 22. Both the iron-rich and
normaldiet groupswere thendivided in two subgroups (n=12 in each)
that received or did not receive phlebotomies. Phlebotomies were
performed at days 0, 7, and 14 and consisted of awithdrawal of 300 µl of
blood from the retro-orbital sinus. Six mice of each subgroup were
sacriﬁced at days 14 and 22. Fig. 1 shows an overall view of the different
treatment conditions. At sacriﬁce, the blood, liver, and spleen were
collected. The liver and spleen were weighed and ﬁxed in 4%
formaldehyde or immediately frozen in liquid nitrogen. Part of the
blood was used immediately for haemoglobin measurements and the
remaining blood was centrifuged to isolate the plasma.
2.2. Blood analysis
Haemoglobin levels were determined with an ABL725 (Radiom-
eter; Copenhagen, Denmark). The plasma isolated by centrifugation
was used to measure serum iron concentrations by spectrophotom-
etry with the Ferene-S method (Ferentest, Biomerieux) on a Cobas
Mira analyzer (Roche). The total iron binding capacity (TIBC) was
determined with the Ramsay protocol (TIBC kit, Biomerieux). The
transferrin saturation was then calculated as (plasma iron/
TIBC)×100. The non-transferrin bound iron was measured according
to a previously reported method [27].
2.3. Tissue iron determination
Iron concentration was measured in the liver and spleen with the
Barry and Sherlockmethod [28]. Perls' staining [29] was performed on
parafﬁn embedded, 5 µm slices of liver and spleen to localise cellular
iron stores.
2.4. RNA extraction and quantitative RT-PCR
Total RNA was extracted with the SV Total RNA Isolation System
(Promega®, Madison, WI). Quality-checked RNA (1 µg) was used for
reverse transcription according to the manufacturer's protocol
(M-MLV-RT, Promega®, Madison, WI). We performed real time
polymerase chain reactions (PCRs) in triplicate to evaluate thel (0% iron) diet, all the mice (n=30 for each condition) were put on a normal diet (D0).
ice served as controls. Six animals were sacriﬁced (culled) at each indicated time point
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(TfRc), and C-reactive protein (CRP) gene expression levels in each
sample; levels were compared to the levels of 18s RNA as an internal
standard. PCR was performed with a qPCR MasterMix Plus for
SYBR®Green I according to the manufacturer's instructions (Euro-
gentec®, Seraing, Belgium). Primer sequences used for the ampli-
ﬁcation are described in Table 1. The PCR was run on an ABI PRISM
7000 sequence detection system (Applied Bioscience, London,
United Kingdom) with the following protocol: 95 °C for 10 min,
followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The PCR
products were checked by sequencing.
For each sample, Hamp1, Slc40a1, Tfrc, and CRP mRNA cycle
threshold (Ct) values were normalised with 18s RNA Ct values. The
normalised Ct values of the samples treatedwith iron overload and/or
phlebotomies were compared to the normalised Ct values obtained
from corresponding untreated control tissues from mice that
were sacriﬁced at day 0 (standards). Results were expressed as the
ratio of the sample versus the standard in arbitrary units (AU) for
convenience.2.5. Immunoblotting
Membrane extracts were prepared from nitrogen frozen spleens
and livers [30]. Protein concentrations were determined with a BC
Assay (Uptima, Interchim); then, 25 µg (spleens) or 50 µg (livers)
samples were loaded onto NuPAGE® Bis-Tris 4–12% gels bathed in
MOPS buffer, following the manufacturer's instructions (Invitrogen,
Carlsbad, CA, USA). The separated proteins were transferred onto
nitrocellulosemembrane and blockedwith 7%milk in TBST (NaCl 0.9%;
Tris–HCl 10 mM, pH7.5; 0.15% Tween20). Membranes were then
incubated with rabbit anti-mouse ferroportin polyclonal antibodies
diluted at 1/100 in TBST with 7% milk [30]. After further washing in
TBST, membranes were incubated in the presence of a goat anti-rabbit
IgG peroxidase-labelled antibody (1/150,000, Jackson) and signals
were visualised with chemiluminescence (Super signal® west dura,
Pierce). As a control, membranes were stripped with RestoreWestern
Blot Buffer (Pierce), incubated for 2 hwithmouse anti-Hsc70 antibody
(B-6; SC-7298; Santa Cruz) diluted at 1/10,000 in TBST with 7% milk,
and then washed in TBST. Finally, these membranes were incubated
with a goat anti-mouse IgG peroxidase-labelled antibody (1/5000,
Dako) and washed with TBST before signal visualisation with
chemiluminescence (Super signal® west pico, Pierce).2.6. Statistical analysis
The statistical analysis was performed with Statview software
(SAS institute, Cary, NC). Non parametric tests were used, including
the Mann–Whitney and Kruskall–Wallis tests. A p-value of less than
0.05 was considered statistically signiﬁcant.Table 1
Primers used in quantitative RT-PCR to measure mRNA levels of Hamp1, Slc40a1, Tfrc,
and CRP standardised with 18s RNA.
Gene Forward primer Reverse primer
Hamp1 5′-CCTATCTCCATCAACAGATG-
3′
5′-AACAGATACCACACTGGGAA-3′
Slc40a1 5′-GCTGCTAGAATCGGTCTTTGG
T-3′
5′-CAGCAACTGTGTCACCGTCAA-3′
Tfrc 5′-TCATGAGGGAAATCAATGAT
CGTA-3′
5′-GCCCCAGAAGATATGTCGGAA-3′
CRP 5′-TTGTCCTTTTCTCAGCAGCCA-
3′
5′-AAAGACAGAACCCTATATGAAGAGC
TAGAG-3′
18s 5′-AGCTAATACATGCCGACGGG-
3′
5′-GGAGCTCACCGGGTTGG-3′3. Results
3.1. Impacts of iron loading and phlebotomy on blood iron parameters
At day 0, transferrin saturation was signiﬁcantly increased in
animals fed an iron-rich diet compared to those fed a normal diet
(Fig. 2A). However, the iron overload did not signiﬁcantly modulate
haemoglobin levels (Fig. 2B). At days 14 and 22, the control animals
displayed no changes in transferrin saturation or haemoglobin levels.
In contrast, iron-loaded mice displayed a signiﬁcant decrease in
transferrin saturation compared to that observed at D0 and compared
to control animals at D14 and D22.
In control mice fed a normal diet, phlebotomies had no impact on
transferrin saturation or haemoglobin levels until D22, compared to
D0 (Fig. 2). Conversely, in mice fed an iron-rich diet, phlebotomies
induced signiﬁcant decreases in transferrin saturation and haemo-
globin levels compared to control animals, with or without
phlebotomies, and compared to non-phlebotomized iron-loaded
animals.
3.2. Impacts of iron loading and phlebotomies on iron stores
Mice fed an iron-rich diet presented signiﬁcantly higher hepatic
iron concentrations (HIC) at day 0 compared tomice fed a normal dietFig. 2. Transferrin saturation and haemoglobin levels. Transferrin saturation (A) and
haemoglobin levels (B) were measured in mice fed a diet supplemented with 0%
(squares) or 3% (triangles) carbonyl iron. In each group, phlebotomies were given to
half the mice (grey symbols) and not to the other half (black symbols). Bars represent
mean +/− standard deviation (n=5 to7). * Statistically different from D0;
& statistically different from the corresponding control (0%) condition; # statistically
different from the corresponding non-phlebotomised condition.
Fig. 3. Hepatic and splenic iron concentrations. Hepatic (A) and splenic (B) iron
concentrations (HIC and SIC, respectively) of mice fed a diet supplemented with 0%
(squares) or 3% (triangles) carbonyl iron. In each group, phlebotomies were given to
half the mice (grey symbols) and not to the other half (black symbols). Each bar
represents mean +/− standard deviation (n=5 to7). * Statistically different from D0;
& statistically different from the corresponding control (0%) condition; # statistically
different from the corresponding non-phlebotomised condition. Note that the scales on
the Y-axes are different in (A) and (B) due to a higher basal level of iron in the spleen
compared to the liver.
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gradient decreasing towards the centres of the lobules (Fig. 4C).
Whether mice were fed iron-rich or normal diets, phlebotomies
did not induce modulations of HIC compared to non-phlebotomized
animals on D0 and D22 (Fig. 3A). The lack of change in hepatic iron
deposits was judged both by the intensity of the stain and by the
nature of the cell population stained (hepatocytic but not macro-
phagic) (Fig. 4 A–D).
Splenic iron concentrations (SIC) were also elevated at day 0 in
mice fed the iron-enriched diet compared to those fed the normal diet
(Figs. 3B, 4E, and G). Despite the return to a normal diet from D0 to
D22, splenic iron accumulated in iron-loaded mice until it reached a
plateau at D14.
Phlebotomies in control mice progressively induced a decrease in
SIC. The difference in SIC compared to control mice without
phlebotomies became signiﬁcant at D22 (Fig. 3B). In contrast,
phlebotomies in iron-loaded mice did not cause SIC increases or
decreases between day 0 and day 22. Thus, the phlebotomies
counteracted the accumulation of splenic iron after iron loading
(Fig. 3B). In all conditions, iron was mainly localised within the red
pulp cells of the spleen (Fig. 4E–H).
3.3. Impacts of iron loading and phlebotomies on mRNA levels of iron
metabolism genes
In the liver, TfrcmRNA levelswere signiﬁcantly decreased fromD0 to
D22 in iron-loaded mice compared to control mice (Fig. 5A). Phlebot-
omies did not signiﬁcantly modulate the expression of this gene in
controls or iron-loaded mice. Furthermore, the hepatic mRNA levels of
Slc40a1 were not signiﬁcantly affected by iron enrichment or phlebot-
omies (Fig. 5B). As expected, the Hamp1 mRNA levels at D0 were
increased in the livers of mice fed the iron-rich diet compared to mice
fed the normal diet (Fig. 5C). Between day 0 and day 22, when mice on
iron-rich diet were switched to a normal diet, this expression level
decreased slightly, but remained higher than the Hamp1 mRNA levels
found in control mice. Phlebotomies had no impact on hepatic Hamp1
mRNA levels in control mice. In contrast, phlebotomies induced a
signiﬁcant decrease in Hamp1 mRNA levels of iron-loaded mice;
nevertheless, the levels remained higher than in control mice at D22
(Fig. 5C). Neither iron enrichment nor phlebotomies had any impact on
the hepatic mRNA levels of CRP at D0 and D22 (data not shown).
In the spleen, mice fed an iron-rich diet displayed higher levels of
TfrcmRNA at D0 compared to control mice, despite the increase in SIC
(Fig. 6A). At D22, Tfrc mRNA expression decreased to basal levels in
mice that were not phlebotomised. Phlebotomies had no signiﬁcant
effect on splenic Tfrc mRNA levels in control mice fed a normal diet
(Fig. 6A). Conversely, in iron-loaded mice with phlebotomies, the
levels of Tfrc mRNA in the spleen remained high on day 22 compared
to mice fed a normal diet without phlebotomies. At D0, mice fed an
iron-rich diet showed increased splenic Slc40A1 mRNA levels
compared to control mice (Fig. 6B). However, at day 22, the
expression decreased in both diet groups compared to day 0.
Phlebotomies induced no signiﬁcant changes in splenic Slc40A1
mRNA expression compared to mice without phlebotomies in both
diet groups. Hamp1 mRNA levels in the spleen were weak with large
standard deviations; thus, no statistical differences could be detected
among the different treatments (data not shown).
Dmt1 and DcytbmRNA levels were also studied in the duodenum;
but these did not show any modulations with diet or phlebotomy
treatments (data not shown).
3.4. Impacts of iron loading and phlebotomies on ferroportin protein
expression
In the liver, membrane protein extracts obtained from the dif-
ferent mice groups at D0 and D22 were examined for ferroportinprotein expression levels (data not shown). Under our assay conditions,
all detectable signals were too faint for interpretation.
In the spleen, we were able to detect high levels of ferroportin
expression at D0. Compared to mice fed the normal diet, mice fed the
iron-rich diet displayed a decrease in ferroportin protein expression
(Fig. 7A), despite increased mRNA levels (Fig. 6B). The difference was
most pronounced at D22 (Fig. 7B). Phlebotomies induced a slight
decrease of ferroportin expression in control animals; in contrast,
phlebotomies induced an increase in ferroportin protein expression in
iron-loaded mice (Fig. 7B, lower panel).
For an overall view of the different parameters studied, the results
are schematically summarised in Table 2.
4. Discussion
During chronic liver disease with secondary hepatic iron deposi-
tion, phlebotomies have been proposed as a treatment to prevent iron
toxicity (reviewed in: [31]). Our goal was to evaluate, in a model of
secondary iron overload, the kinetics of ironmobilisation produced by
phlebotomies in connection with modulated iron metabolism gene
Fig. 4. Hepatic and splenic iron distributions. Perls' staining of representative livers (A–D) and spleens (E–H) show locations of iron stores in mice fed a diet supplemented with 0%
(upper panels) or 3% (lower panels) carbonyl iron. Iron stores in livers of mice that received phlebotomies (left panels) or did not receive phlebotomies (right panels) are compared.
Magniﬁcation was 100 times.
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murine model [26]. Conversely to the secondary iron overload
observed in Beta-thalassemic mice and humans which present with
a strong decrease of hepcidin expression and cannot be phleboto-
mized, due to the anaemia related to this haematological disease
[32,33], carbonyl iron-loaded animals are not known to have
haematological abnormalities and have an hepcidin expression
increase [4]. We then mobilised iron stores with mild phlebotomies
that mimicked those performed in human patients, especially during
dysmetabolic hepatosiderosis in which hepcidin expression is
increased [34]. The 0.3 ml of blood removed from a 30 g mouse was
equivalent to about 13% of the total blood volume. This was similar to
the 10% of total blood volume removedwith a 500 ml phlebotomy in a
human being.
On the day dietary iron supplementation was withdrawn (D0),
iron deposits were foundmainlywithin hepatocytes in the liver and in
cells of the splenic red pulp, which are known to comprise primarily
macrophages [35].
In the liver, we observed an absence of iron deposits within
resident macrophages; this contrasted with ﬁndings in anothermouse strain treated with carbonyl iron overload [26]. This
discrepancy could be explained by the discovery of the C57Bl/6-
speciﬁc gain of function mutation in the Mon1a gene. The Mon1a
gene product is a protein implicated in vesicular trafﬁcking of the
ferroportin protein to the cell membrane [36]. However, that report
emphasised that the major phenotype of the Mon1a mutation was
an alteration in the spleen. In our model, we did observe some
hepatic consequences of iron overload, including an increase of
hepcidin1 unrelated to inﬂammation and a decrease of transferrin
receptor 1 mRNA levels. Both these changes were expected with iron
overloading [37]. In addition, there were no modulations of hepatic
ferroportin mRNA levels; the ferroportin protein was not clearly
detectable.
In the spleen, we found that ferroportin protein expression was
decreased with iron overloading. This could be a consequence of
inducing hepatic hepcidin expression. Indeed, it has been reported
that increased hepcidin expression may inhibit iron egress from
splenic macrophages and thus contribute to the development of
splenic iron overload [38]. In addition, in the spleens of iron-loaded
mice, we found increased TfRc mRNA levels, which were maintained
Fig. 5. Hepatic mRNA expression of iron metabolism genes. Hepatic mRNA levels of (A)
Tfrc, (B) Slc40a1, and (C) Hamp1 were determined by quantitative RT-PCR in groups of
mice fed a diet supplemented with 0% (squares) or 3% (triangles) carbonyl iron. In each
group, phlebotomies were given to half the mice (grey symbols) and not to the other
half (black symbols). Note that the Y-scales are different in each panel, and reﬂect the
units for each measured parameter. Each bar represents the mean +/− standard
deviation (n=5 to 7). * Statistically different from D0; & statistically different from the
corresponding control (0%) condition; # statistically different from the corresponding
non-phlebotomized condition.
Fig. 6. SplenicmRNA expression of ironmetabolismgenes. SplenicmRNA levels of (A) Tfrc
and (B) Slc40a1 were determined by quantitative RT-PCR in groups of mice fed a diet
supplemented with 0% (squares) or 3% (triangles) carbonyl iron. In each group,
phlebotomies were given to half the mice (grey symbols) and not to the other
half (black symbols). Each bar represents the mean +/− standard deviation (n=5 to 7).
* Statistically different fromD0; & statistically different from the corresponding control (0%)
condition; # statistically different from the corresponding non-phlebotomized condition.
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undeﬁned, regulatory mechanism for TfRcmRNA production that may
overcome regulation due to the binding of iron regulatory protein 1 to
an iron-responsive element in the spleen. This undeﬁned regulation
system could be related to that responsible for the induction of TfRcmRNA found, despite high ambient iron levels, during erythropoiesis
[39,40].
The switch to a normal diet from the iron-rich diet led to a
decrease in transferrin saturation at D22. Nevertheless, hepatic iron
concentrations remained steady and splenic iron increased. These
results demonstrated that a secondary iron overload could unexpect-
edly induce a decrease in plasma iron bioavailability through splenic
iron sequestration, even when animals were fed a normal diet. This
was possibly related to the expression levels of hepatic hepcidin,
which remained higher in iron-loaded mice than in control animals,
despite a slight decrease compared to the levels at D0.
Our results support the hypothesis that hepatic hepcidin over-
expression has a major effect on splenic macrophage iron export
function. This was reinforced by the fact that, despite the increase in
splenic ferroportin mRNA levels in iron-loaded mice, there was a
strong decrease in ferroportin protein expression. Our results in iron-
loaded mice indicated that the hepcidin inhibition of ferroportin
expression [8] overcame transcriptional and post-transcriptional
signals related to increasing the cellular iron stores within the spleen
[41,42].
Interestingly, the effects of hepcidin were not detected in the livers
of iron-loadedmice. Indeed, the switch to a normal diet did not induce
iron accumulation within Kupffer cells, as it did in spleen cells, and did
not modulate the liver iron content or distribution. Taken together,
Fig. 7. Splenic ferroportin protein detection by immunoblotting. Ferroportin protein
(fpn)was analysed bywestern blot in the spleens ofmice. Anti-Hsc70 antibodywas used
as a loading control. (A) Impact of the iron-enriched diet (3%) on ferroportin protein
expression levels was analysed at day 0 (D0). (B) Impact of the iron-enriched diet
with phlebotomies (3%P) on ferroportin protein expression levels was analysed at day
22 (D22) for mice fed a normal diet (0%) andmice fed an iron-enriched diet (3%; n=3).
Table 2
Schematic overview of all the parameter modulations. For a given condition, the effect is
compared to control mice fed a normal diet without phlebotomies at the corresponding
timepoint. Thenumberof arrows indicates thedegreeof the effect, and thedarkness of the
cells indicates the amplitude of the variation within a parameter; darker = higher
amplitude; lighter = lower amplitude.
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cells, may be less sensitive to the regulatory effects of hepcidin on iron
metabolism. This hypothesis was reinforced by the fact that we could
not clearly detect an induction of ferroportin protein expression in
iron-loaded livers compared to control livers.
The phlebotomy treatments provided an opportunity for analysing
the kinetics of iron mobilisation in parallel with hepcidin and
ferroportin expression.
In animals fed a normal diet, phlebotomies had no impact on blood
iron parameters. The maintenance of sufﬁcient plasma iron bioavail-
ability was partly related to a decrease in SIC, which attested to an
increase of iron egress from macrophages. However, relative to
splenic weight, the SIC decrease was apparently insufﬁcient to
adequately compensate for the iron loss due to venesection. Thus,
iron levels were also likely maintained through: i) iron mobilisation
from other macrophage compartments and ii) digestive iron absorp-
tion [9]. The latter pathway was considered due to previous reports
that described the fulﬁlment of iron needs via intestinal iron
absorption and ferroportin protein induction at the basal membranes
of enterocytes [5,43,44]; this pathway was also described under
conditions of hepcidin deﬁciency [45]. It must be noted that control
animals did not display disturbances of plasma iron parameters or
anaemia; therefore no hypoxia and no decrease in hepatic hepcidin1
mRNA expression occurred; this suggested that animals could strictly
compensate for iron losses despite the erythroid activity induced by
phlebotomies. This result was surprising, in light of recent results that
suggested that erythropoietic activity was a determinant in the
inhibition of hepcidin mRNA expression [46,47]. In this study, a
decrease of ferroportin protein levels was observed in the absence of
hepcidin modulation. This could indicate that partial compensation
for iron loss was accomplished by using most of the iron provided in
the normal diet; thus, the subsequent storage in splenic cells was
limited and led to the global decrease in splenic iron. These conditions
gave rise to the prominent role of transcriptional and post-
transcriptional regulation of ferroportin gene expression.
In animals fed an iron-rich diet, the effect of switching to a normal
diet was emphasised with the phlebotomies. The presence of plasma
iron deﬁciency was indicated by anaemia. Inadequate iron mobilisa-tion from the spleen may have, at least partly, accounted for the
maintenance of splenic iron between D0 and D22. This inertia in the
splenic response to maintain plasma iron bioavailability was most
likely related to an abnormally high level of hepcidin expression.
Indeed, in this anaemic group, the hepcidin mRNA levels remained
higher than those found in mice fed a normal diet with or without
phlebotomies, but were lower than those found in mice fed an iron-
rich diet without phlebotomies. The decrease in hepcidin expression
permitted higher ferroportin expression on cell membranes; hence,
this explains the increase in ferroportin protein expression found in
iron-loaded mice with phlebotomies compared to those without
phlebotomies. However, the poor phlebotomy tolerance in iron-
loaded mice indicated that the decrease in hepcidin was insufﬁcient
for the normalisation of plasma iron, despite the enhanced ability of
the C57Bl/6 strain to express ferroportin protein at the cellular
membrane due to the mutation in Mon1a gene [36].
The results of this study raised questions concerning the biological
impact of ferroportin in the liver, due to the absence of hepatic iron
mobilisation in iron-loaded phlebotomized mice and the putative low
sensitivity of hepatic cells to hepcidin, as previously discussed. A
previous study also raised doubts about the responsiveness of
hepatocytes to hepcidin through potential ferroportin protein
regulation [48]. We did not further investigate this point in this
study, because it would have been risky to force higher levels of iron
mobilisation from hepatic cells by increasing the amount of blood
withdrawn; the iron-enriched mice were already in an anaemic state
after the mild phlebotomies. However, future investigations could be
performed in mice that do not adequately modulate hepcidin levels in
response to iron store levels (i.e., HFE−/− mice).
In conclusion, our results demonstrated that in our model of
secondary iron overload: i) a decrease of plasma iron bioavailability
was present, ii) iron mobilisation by venesection primarily originated
from the spleen and probably partly from enterocytes and iii) hepatic
346 E. Camberlein et al. / Biochimica et Biophysica Acta 1802 (2010) 339–346iron storeswere notmobilised at this stage. This suggested that, during
secondary iron overload with an increase in hepcidin expression,
phlebotomies might be not entirely appropriate for mobilising
excessive hepatic iron. Taken together, these data suggest that: i) a
plasma hepcidin assay could be useful for monitoring hepcidin levels
before and during venesections in patients with secondary iron
overload that are eligible for phlebotomy, and ii) it may be appropriate
to consider the use of iron chelators in these circumstances.
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